Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes ...
Yahoo Finance

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

SAN DIEGO, July 16, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to ...
Yahoo Finance

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing ...
Business Wire

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
Nasdaq

Revelation Bio To Share New Data From PRIME Study Of Gemini In March

(RTTNews) - Revelation Biosciences Inc. (REVB) is preparing to showcase new clinical data that could mark an important step forward in the treatment of kidney disease. The company announced that ...